Nov 5 (Reuters) - Celltrion:
* CELLTRION PRESENTS EFFICACY AND SAFETY DATA FOR POTENTIAL
COVID-19 TREATMENT CANDIDATE CT-P59 IN PATIENTS WITH MILD
SYMPTOMS
* CELLTRION - TRIAL RESULTS INDICATE TREATMENT WITH CT-P59
RESULTED IN AT LEAST 44% FASTER RECOVERY TIME WHEN COMPARED WITH
PLACEBO
* CELLTRION - NO PATIENTS TREATED WITH CT-P59 IN STUDY HAVE
SO FAR
REQUIRED HOSPITALISATION OR OTHER ANTIVIRAL THERAPY AS A RESULT
OF COVID-19
* CELLTRION- CT-P59 WAS WELL TOLERATED WITH NO CLINICALLY
SIGNIFICANT SAFETY ISSUES SEEN IN STUDY POPULATION
* CELLTRION - ANNOUNCED RESULTS FROM ONGOING PHASE I
CLINICAL
TRIAL OF CT-P59, AN ANTI-COVID-19 MONOCLONAL ANTIBODY TREATMENT
CANDIDATE
Source text for Eikon: ID:nBwVGxwla
Further company coverage: 068270.KS 091990.KQ
((Reuters.Briefs@thomsonreuters.com;))